Intubated ICU PatientsNCT07711405
Association of Arterio-Venous Oxygen and Carbon Dioxide Gradients With Tissue Hypoperfusion and Mortality in Sepsis
An observational study of Intubated ICU Patients and Sepsis and Septic Shock, run by Gaziosmanpasa Research and Education Hospital at 1 site in Turkey (Türkiye).
Trial summary
In patients with sepsis who are treated in the intensive care unit under invasive mechanical ventilation, the combined evaluation of ScvO₂ and PcvCO₂ may provide a comprehensive insight into tissue oxygenation and metabolic stress, allowing a more precise hemodynamic assessment in critically ill patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Intubated ICU Patients, Sepsis and Septic Shock
- How many people
- 88 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Mar 2025to 13 Jan 2026
- How long will I take part?
- 28 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: İntubated icu patients who diagnosed with sepsis
Who may be able to join
- Adult patients aged 18 years or older
- Diagnosis of sepsis
- Admission to the intensive care unit
- Intubated and receiving invasive mechanical ventilation
- Presence of a central venous catheter
Who cannot join
- Patients younger than 18 years
- Patients in whom a central venous catheter cannot be placed
- Patients receiving oxygen therapy via face mask or nasal cannula
- Patients treated with non-invasive mechanical ventilation
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Gaziosmanpasa Training and Research Hospital
Istanbul, Gaziosmanpasa, 34255
About this study
In patients with sepsis who are treated in the intensive care unit under invasive mechanical ventilation, the combined evaluation of ScvO₂ and PcvCO₂ may provide a comprehensive insight into tissue oxygenation and metabolic stress, allowing a more precise hemodynamic assessment in critically ill patients. The aim of this study is to evaluate the monitoring of ScvO₂, PcvCO₂, and EtCO₂ in intensive care patients in order to predict hemodynamic instability, 28-day mortality, and length of ICU stay, as well as to investigate their effects on cardiac output, tissue oxygenation, and hypoperfusion.
Read the detailed description
In intubated patients admitted to the intensive care unit due to sepsis and receiving inotropic support, placement of a central venous catheter and blood gas analysis, as well as radial artery cannulation for invasive hemodynamic monitoring, are routinely performed. In these patients, ScvO₂ and ScvCO₂ measurements are obtained via the central venous catheter. End-tidal CO₂ (EtCO₂) is measured using capnography. Arterial blood gas analysis, including SaO₂ and PaCO₂, is performed through the radial arterial catheter. Data recorded at admission and at 6, 12, and 24 hours will be evaluated. Additional hemodynamic parameters, including heart rate, blood pressure, arterial blood gas values (pH, PaCO₂, HCO₃-), serum lactate levels, and cardiac output, will also be analyzed. Finger-tip perfusion index is measured using a pulse oximetry probe. Outcomes such as duration of mechanical ventilation, length of ICU stay, and 28-day mortality and morbidity will be assessed in conjunction with APACHE II and SOFA scores.
- Conditions
- Intubated ICU Patients, Sepsis and Septic Shock
- Keywords
- sepsis, central venous carbondiokside, carbondiokside gradient, sepsis mortality, mortality prediction, central venous to arterial carbondiokside
- Medical subject headings
- Sepsis, Shock, Septic
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation of the central venous-arterial carbon dioxide difference with 28-day mortality
The primary outcome of this study is to evaluate the correlation between the central venous-arterial carbon dioxide difference and mortality in patients with sepsis admitted to the intensive care unit. The central venous-arterial carbon dioxide difference will be calculated using paired central venous and arterial blood gas samples obtained at predefined time points (at admission and at 6, 12, and 24 hours). Mortality will be assessed as 28-day all-cause mortality. The correlation between the carbon dioxide difference and mortality will be analyzed to determine its potential value as an indicator of mortality
Measured: from march 2025 to january 2026
Secondary outcomes (1)
Predictive accuracy of perfusion parameters and APACHE II score for 28-day mortality
The predictive accuracy of central venous-to-arterial carbon dioxide difference (Pcv-aCO₂), end-tidal carbon dioxide (EtCO₂), serum lactate concentration, and APACHE II score for 28-day all-cause mortality will be assessed using the area under the receiver operating characteristic curve (AUC-ROC) in patients with sepsis and septic shock. Each parameter will be evaluated separately for its discriminatory ability to predict mortality.
Measured: february 2025 to january 2026
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2026
- Study start1 Mar 2025
- Primary completion20 Sep 2025
- Study completion13 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intubated ICU PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 88 participants (actual)
- Target duration
- 28 Days
Sponsor and investigators
- Lead sponsor
- Gaziosmanpasa Research and Education Hospital
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07711405
- Sponsor's protocol ID
- GaziosmanpasaTREH26022025
- Status last verified
- May 2026
- First submitted
- 25 Dec 2025
- Last updated
- 17 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No. Individual participant data will not be shared.
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association of Arterio-Venous Oxygen and Carbon Dioxide Gradients With Tissue Hypoperfusion and Mortality in Sepsis
- ClinicalTrials.gov ID
- NCT07711405
- Acronym / sponsor ID
- GaziosmanpasaTREH26022025
- Conditions
- Intubated ICU Patients, Sepsis and Septic Shock
- Keywords
- sepsis, central venous carbondiokside, carbondiokside gradient, sepsis mortality, mortality prediction, central venous to arterial carbondiokside
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 88 participants (actual)
- Lead sponsor
- Gaziosmanpasa Research and Education HospitalOther government
- Study start
- 1 Mar 2025 (actual)
- Primary completion
- 20 Sep 2025 (actual)
- Study completion
- 13 Jan 2026 (actual)
- First posted
- 17 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In patients with sepsis who are treated in the intensive care unit under invasive mechanical ventilation, the combined evaluation of ScvO₂ and PcvCO₂ may provide a comprehensive insight into tissue oxygenation and metabolic stress, allowing a more precise hemodynamic assessment in critically ill patients. The aim of this study is to evaluate the monitoring of ScvO₂, PcvCO₂, and EtCO₂ in intensive care patients in order to predict hemodynamic instability, 28-day mortality, and length of ICU stay, as well as to investigate their effects on cardiac output, tissue oxygenation, and hypoperfusion.
Detailed description
In intubated patients admitted to the intensive care unit due to sepsis and receiving inotropic support, placement of a central venous catheter and blood gas analysis, as well as radial artery cannulation for invasive hemodynamic monitoring, are routinely performed. In these patients, ScvO₂ and ScvCO₂ measurements are obtained via the central venous catheter. End-tidal CO₂ (EtCO₂) is measured using capnography. Arterial blood gas analysis, including SaO₂ and PaCO₂, is performed through the radial arterial catheter. Data recorded at admission and at 6, 12, and 24 hours will be evaluated. Additional hemodynamic parameters, including heart rate, blood pressure, arterial blood gas values (pH, PaCO₂, HCO₃-), serum lactate levels, and cardiac output, will also be analyzed. Finger-tip perfusion index is measured using a pulse oximetry probe. Outcomes such as duration of mechanical ventilation, length of ICU stay, and 28-day mortality and morbidity will be assessed in conjunction with APACHE II and SOFA scores.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 28 Days
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- İntubated icu patients who diagnosed with sepsis
Key inclusion criteria (5 listed)
- Adult patients aged 18 years or older
- Diagnosis of sepsis
- Admission to the intensive care unit
- Intubated and receiving invasive mechanical ventilation
- Presence of a central venous catheter
Key exclusion criteria (4 listed)
- Patients younger than 18 years
- Patients in whom a central venous catheter cannot be placed
- Patients receiving oxygen therapy via face mask or nasal cannula
- Patients treated with non-invasive mechanical ventilation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Correlation of the central venous-arterial carbon dioxide difference with 28-day mortality
Time frame: from march 2025 to january 2026
The primary outcome of this study is to evaluate the correlation between the central venous-arterial carbon dioxide difference and mortality in patients with sepsis admitted to the intensive care unit. The central venous-arterial carbon dioxide difference will be calculated using paired central venous and arterial blood gas samples obtained at predefined time points (at admission and at 6, 12, and 24 hours). Mortality will be assessed as 28-day all-cause mortality. The correlation between the carbon dioxide difference and mortality will be analyzed to determine its potential value as an indicator of mortality
1 secondary outcome
Predictive accuracy of perfusion parameters and APACHE II score for 28-day mortality
Time frame: february 2025 to january 2026
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
- Individual participant dataSharing planned: No. No. Individual participant data will not be shared.
Related trials for Intubated ICU Patients
Recruiting
Impact of the Choice of Gastric Tube Placement Sites on the Incidence of Ventilator Associated Pneumonia
Intubated Patient Requiring a Gastric Tube
Recruiting
The Effects of Endotracheal Suctioning on Pain and Serum Markers
Intensive Care Unit ICU, Intubation
RecruitingObservational study
Innate Immune Immunoparalysis and Ventilator-Associated Pneumonia in Critically Ill Elderly Patients
Intubated ICU Patients, Ventilator Associated Pneumonia ( VAP)
Not yet recruiting
Ventilator Study in the NICU
Neuro-intensive Care Unit Patients
RecruitingObservational study
Development and Validation of a Mouth Assessment Tool for Orally Intubated Patients in Intensive Care Unit)
Intensive Care
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Intubated ICU Patients and Sepsis and Septic Shock, run by Gaziosmanpasa Research and Education Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation of the central venous-arterial carbon dioxide difference with 28-day mortality (time frame: from march 2025 to january 2026). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.